<DOC>
	<DOCNO>NCT02125071</DOCNO>
	<brief_summary>An exploratory clinical trial evaluate pharmacokinetic characteristic I.V . Hepabig injection use prevention hepatitis B relapse liver transplantation .</brief_summary>
	<brief_title>Study Pharmacokinetic Characteristics I.V . Hepabig Injection Used Prevention Hepatitis B Relapse After Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Male female â‰¤18 year old Patients understand inform consent form sign form voluntarily Patients underwent liver transplantation due HBV related disease treat prevention hepatitis B relapse liver transplantation Multiorgan recipient reimplantation IgA Deficiency Serious nephropathy Serious cardiovascular system failure within 6 month Ischemic hemolytic anemia Condition immunosuppression immunodeficiency Hypersensitivity allergic blood product HIV HCV positive Participation clinical trial within 3 month Pregnancy breast feed Those investigator determines inappropriate participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>